Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Immunotherapy with Long-Lived Anti-CD38 × Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human Myeloma Cell Lines and CD38+ Cells in Monkeys: A Potential Therapy for Multiple Myeloma

Seung Y. Chu, PhD, Yvonne Miranda, MS, Sheryl Phung, MS, Hsing Chen, MS, Rumana Rashid, PhD, Nancy A. Endo, BS, Emily W. Chan, BS, Erik Pong, MS, Christine Bonzon, PhD, Umesh S. Muchhal, PhD, Irene W.L. Leung, PhD, Matthew J. Bernett, PhD, Gregory L. Moore, PhD, David E. Szymkowski, PhD, John R. Desjarlais, PhD

Blood (2014) 124 (21): 4727.

https://doi.org/10.1182/blood.V124.21.4727.4727

Published: 2014

Journal Articles

Immunotherapy with Long-Lived Anti-CD20 × Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human B Cell Lines and of Circulating and Lymphoid B Cells in Monkeys: A Potential Therapy for B Cell Lymphomas and Leukemias

Seung Y. Chu, PhD, Sung-Hyung Lee, PhD, Rumana Rashid, PhD, Hsing Chen, MS, Emily W. Chan, BS, Sheryl Phung, MS, Erik Pong, MS, Nancy A. Endo, BS, Yvonne Miranda, MS, Christine Bonzon, PhD, Irene W.L. Leung, PhD, Umesh S. Muchhal, PhD, Gregory L. Moore, PhD, Matthew J. Bernett, PhD, David E. Szymkowski, PhD, John R. Desjarlais, PhD

Blood (2014) 124 (21): 3111.

https://doi.org/10.1182/blood.V124.21.3111.3111

Published: 2014

Journal Articles

Immunotherapy with Long-Lived Anti-CD123 × Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human AML Cell Lines and of CD123+ Cells in Monkeys: A Potential Therapy for Acute Myelogenous Leukemia

Seung Y. Chu, PhD, Erik Pong, MS, Hsing Chen, MS, Sheryl Phung, MS, Emily W. Chan, BS, Nancy A. Endo, BS, Rumana Rashid, PhD, Christine Bonzon, PhD, Irene W.L. Leung, PhD, Umesh S. Muchhal, PhD, Gregory L. Moore, PhD, Matthew J. Bernett, PhD, David E. Szymkowski, PhD, John R. Desjarlais, PhD

Blood (2014) 124 (21): 2316.

https://doi.org/10.1182/blood.V124.21.2316.2316

Published: 2014

Journal Articles

XmAb®5574, An Fc Engineered Humanized Anti-CD19 Monoclonal Antibody, Has Potent in Vitro and in Vivo Activities, and Has the Potential for Treating B Cell Malignancies

Chris E Lawrence, PhD, Jonathan Zalevsky, PhD, Holly Horton, PhD, Irene Leung, PhD, Seung Chu, PhD, Sher Karki, PhD, Eugene Zhukovsky, PhD, John R Desjarlais, PhD, David F Carmichael, PhD

Blood (2008) 112 (11): 2621.

https://doi.org/10.1182/blood.V112.11.2621.2621

Published: 2008

Journal Articles

XmAb™2513, an Fc Engineered Humanized Anti-CD30 Monoclonal Antibody, Has Potent In Vitro and In Vivo Activities, and Has the Potential for Treating Hematologic Malignancies.

Chris E. Lawrence, PhD, Phil W. Hammond, PhD, Jonathan Zalevsky, PhD, Holly Horton, PhD, Seung Chu, PhD, Sher Karki, PhD, John R. Desjarlais, PhD, David F. Carmichael, PhD

Blood (2007) 110 (11): 2340.

https://doi.org/10.1182/blood.V110.11.2340.2340

Published: 2007

NARROW

Immunotherapy with Long-Lived Anti-CD38 × Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human Myeloma Cell Lines and CD38+ Cells in Monkeys: A Potential Therapy for Multiple Myeloma

Immunotherapy with Long-Lived Anti-CD20 × Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human B Cell Lines and of Circulating and Lymphoid B Cells in Monkeys: A Potential Therapy for B Cell Lymphomas and Leukemias

Immunotherapy with Long-Lived Anti-CD123 × Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human AML Cell Lines and of CD123+ Cells in Monkeys: A Potential Therapy for Acute Myelogenous Leukemia

XmAb®5574, An Fc Engineered Humanized Anti-CD19 Monoclonal Antibody, Has Potent in Vitro and in Vivo Activities, and Has the Potential for Treating B Cell Malignancies

XmAb™2513, an Fc Engineered Humanized Anti-CD30 Monoclonal Antibody, Has Potent In Vitro and In Vivo Activities, and Has the Potential for Treating Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Immunotherapy with Long-Lived Anti-CD38 × Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human Myeloma Cell Lines and CD38+ Cells in Monkeys: A Potential Therapy for Multiple Myeloma

Immunotherapy with Long-Lived Anti-CD20 × Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human B Cell Lines and of Circulating and Lymphoid B Cells in Monkeys: A Potential Therapy for B Cell Lymphomas and Leukemias

Immunotherapy with Long-Lived Anti-CD123 × Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human AML Cell Lines and of CD123+ Cells in Monkeys: A Potential Therapy for Acute Myelogenous Leukemia

XmAb®5574, An Fc Engineered Humanized Anti-CD19 Monoclonal Antibody, Has Potent in Vitro and in Vivo Activities, and Has the Potential for Treating B Cell Malignancies

XmAb™2513, an Fc Engineered Humanized Anti-CD30 Monoclonal Antibody, Has Potent In Vitro and In Vivo Activities, and Has the Potential for Treating Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only